Home » RedHill Biopharma Earns FDA Approval for H. Pylori Treatment
RedHill Biopharma Earns FDA Approval for H. Pylori Treatment
The FDA has approved RedHill Biopharma’s Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules for the treatment of Helicobacter pylori infection in adults.
Talicia is a fixed-dose, all-in-one oral capsule that contains 10 milligrams of omeprazole magnesium, 250 mg of amoxicillin, and 12.5 mg of rifabutin used in combination with a protein pump inhibitor for treating adults infected with H. pylori.
Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based therapies.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May